Link to this page
National Cancer Institute Thesaurus
| Preferred Name | Rosiglitazone Maleate | |
| Synonyms |
ROSIGLITAZONE MALEATE Rosiglitazone Maleate rosiglitazone maleate (+/-)-5-[[4-[2-(Methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione, ( Z )-2-Butenedioate (1:1) Avandia BRL49653 |
|
| Definitions |
The maleate salt of rosiglitazone, an orally-active thiazolidinedione with antidiabetic properties and potential antineoplastic activity. Rosiglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-gamma), a ligand-activated transcription factor, thereby inducing cell differentiation and inhibiting cell growth and angiogenesis. This agent also modulates the transcription of insulin-responsive genes, inhibits macrophage and monocyte activation, and stimulates adipocyte differentiation. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C2583 |
|
| Accepted_Therapeutic_Use_For |
Type 2 diabetes Non-Insulin-Dependent Diabetes Mellitus and Type II Diabetes Mellitus
|
|
| ALT_DEFINITION |
A drug that helps control the amount of glucose (sugar) in the blood and is being studied in the prevention and treatment of some types of cancer. Avandia stops cells from growing and may prevent the growth of new blood vessels that tumors need to grow. It is a type of thiazolidinedione and a type of antiangiogenesis agent.
|
|
| CAS_Registry |
155141-29-0
|
|
| CHEBI_ID |
CHEBI:8892
|
|
| Chemical_Formula |
C18H19N3O3S.C4H4O4
|
|
| code |
C2583
|
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
| Contributing_Source |
CTRP FDA GDC
|
|
| DEFINITION |
The maleate salt of rosiglitazone, an orally-active thiazolidinedione with antidiabetic properties and potential antineoplastic activity. Rosiglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-gamma), a ligand-activated transcription factor, thereby inducing cell differentiation and inhibiting cell growth and angiogenesis. This agent also modulates the transcription of insulin-responsive genes, inhibits macrophage and monocyte activation, and stimulates adipocyte differentiation.
|
|
| Display_Name |
Rosiglitazone Maleate
|
|
| FDA_UNII_Code |
KX2339DP44
|
|
| FULL_SYN |
ROSIGLITAZONE MALEATE Rosiglitazone Maleate rosiglitazone maleate (+/-)-5-[[4-[2-(Methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione, ( Z )-2-Butenedioate (1:1) Avandia BRL49653
|
|
| Has_Free_Acid_Or_Base_Form | ||
| Has_Target | ||
| Is_Value_For_GDC_Property | ||
| label |
Rosiglitazone Maleate
|
|
| Legacy Concept Name |
Rosiglitazone
|
|
| Maps_To |
Rosiglitazone Maleate
|
|
| NCI_Drug_Dictionary_ID |
37793
|
|
| NSC Number |
717764
|
|
| PDQ_Closed_Trial_Search_ID |
37793
|
|
| PDQ_Open_Trial_Search_ID |
37793
|
|
| Preferred_Name |
Rosiglitazone Maleate
|
|
| prefixIRI |
Thesaurus:C2583
|
|
| Semantic_Type |
Pharmacologic Substance
|
|
| UMLS_CUI |
C0795660
|
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |